171 related articles for article (PubMed ID: 38158159)
1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R;
Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M; Kitano S; Ogata N; Mitamura Y; Oh H; Ochi H; Ohsawa S; Hirakata A;
Jpn J Ophthalmol; 2023 May; 67(3):264-279. PubMed ID: 36897413
[TBL] [Abstract][Full Text] [Related]
4. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR
Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.
Ishida S; Chen SJ; Murata T; Ogura Y; Ruamviboonsuk P; Sakamoto T; Fujita T; Kawano M; Ohsawa S; Abreu F; Haskova Z; Ives J; Silverman D; Yoon YH;
Asia Pac J Ophthalmol (Phila); 2023 Sep-Oct 01; 12(5):451-459. PubMed ID: 37851562
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Faricimab vs Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase 3 YOSEMITE/RHINE Trials.
Zarbin M; Tabano D; Ahmed A; Amador M; Ding A; Holekamp N; Lu XY; Stoilov I; Yang M
Ophthalmology; 2024 Jun; ():. PubMed ID: 38852921
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
[TBL] [Abstract][Full Text] [Related]
8. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
Pichi F; Abdi A; Aljneibi S; El Ghrably I; Agarwal A; Ghazi NG
Int Ophthalmol; 2024 Jun; 44(1):275. PubMed ID: 38916818
[TBL] [Abstract][Full Text] [Related]
9. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS; Khanani AM; Quezada Ruiz C; Basu K; Ferrone PJ; Brittain C; Figueroa MS; Lin H; Holz FG; Patel V; Lai TYY; Silverman D; Regillo C; Swaminathan B; Viola F; Cheung CMG; Wong TY;
Lancet; 2022 Feb; 399(10326):729-740. PubMed ID: 35085502
[TBL] [Abstract][Full Text] [Related]
11. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
13. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
Ophthalmology; 2024 Feb; ():. PubMed ID: 38382813
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Tadayoni R; Paris LP; Danzig CJ; Abreu F; Khanani AM; Brittain C; Lai TYY; Haskova Z; Sakamoto T; Kotecha A; Schlottmann PG; Liu Y; Seres A; Retiere AC; Willis JR; Yoon YH;
Ophthalmology; 2024 Jan; ():. PubMed ID: 38280653
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
17. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
[TBL] [Abstract][Full Text] [Related]
20. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
